Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647218 · ClinicalTrials.gov registry record · NA
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
A NA study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT00647218 is a NA study of Breast Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 38 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT00647218, a NA study of Breast Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This clinical trial is studying how well giving paclitaxel together with radiation therapy works in treating patients undergoing surgery for stage II or stage III breast cancer.
Conditions Studied
Interventions
- DRUG Post-operative adjuvant therapy
- DRUG neoadjuvant therapy
- PROCEDURE therapeutic surgical procedure
- RADIATION Radiation therapy with concurrent Paclitaxel
- DRUG Hormonal Therapy
Study Locations (6)
Tennessee
- Williamson Medical Center - Frankling
- Jackson-Madison Hospital - Jackson
- Boston Baskin Cancer Center - Memphis
- Methodist Lebonheur Healthcare - Memphis
- Meharry Medical College - Nashville
- Vanderbilt-Ingram Cancer Cetner - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2000-02 |
| Est. Completion | 2004-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647218
The ClinicalTrials.gov registry entry for NCT00647218 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Post-operative adjuvant therapy is the first listed.
NCT00647218 reports 6 study locations spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00647218 about?
NCT00647218 is a clinical study titled "Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel and radiation therapy before surgery ma...
What is the current status of trial NCT00647218?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2000-02. Estimated completion is 2004-11.
What conditions does trial NCT00647218 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00647218?
The interventions under investigation include: Post-operative adjuvant therapy (DRUG), neoadjuvant therapy (DRUG), therapeutic surgical procedure (PROCEDURE), Radiation therapy with concurrent Paclitaxel (RADIATION), Hormonal Therapy (DRUG).
Who is sponsoring clinical trial NCT00647218?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00647218 being conducted?
This trial has 6 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.